Cannabis and Glaucoma: The Original Medical Marijuana Claim Revisited
Balanced Cannabis Science
30%
Cannabis does lower eye pressure by 25 to 30 percent, but the effect fades in 3 to 4 hours, making it impractical compared to modern treatments that provide 24-hour control with a single daily drop.
Hepler & Frank, JAMA, 1971
Hepler & Frank, JAMA, 1971
View as imageIf you ask most people why medical marijuana first became a topic of public debate, many will say glaucoma. The connection between cannabis and glaucoma is one of the oldest claims in the medical marijuana movement, dating back to the early 1970s. It was the condition that launched Robert Randall's legal battle to access cannabis for medical use in the United States, resulting in the first Compassionate Investigational New Drug program. It is the condition most people over 50 associate with medical cannabis.
It is also a condition where the evidence, once promising, has been thoroughly overtaken by better treatments. Understanding the cannabis-glaucoma story requires looking at the original research, understanding why the effect is real but impractical, and recognizing why ophthalmology has moved decisively in other directions.
Key Takeaways
- Cannabis does lower eye pressure (intraocular pressure), as Hepler and Frank first showed in 1971, but the effect only lasts 3 to 4 hours — so you would need to dose 6 to 8 times a day to maintain steady control
- Modern glaucoma treatments like prostaglandin eye drops, laser trabeculoplasty, and minimally invasive surgery provide 24-hour pressure control with a single daily drop or procedure, making cannabis impractical by comparison
- THC lowers blood pressure body-wide, which can reduce blood flow to the optic nerve — creating a paradox where the drug lowers eye pressure while starving the eye of the nourishment it needs
- The American Academy of Ophthalmology has formally recommended against cannabis for glaucoma, citing impractical dosing, systemic side effects, and the availability of far better alternatives
- Topical cannabinoid eye drops are the most interesting research direction, but formulation problems — cannabinoids are oily, hard to dissolve, and irritating to the eye — have kept them from reaching human trials
- This is not medical advice. Patients with glaucoma should work with their ophthalmologist on a treatment plan using proven therapies
Hepler and Frank, 1971: Where It Started
Cannabis vs Modern Glaucoma Treatments
The paradox: THC lowers eye pressure but also lowers systemic blood pressure — which can reduce blood flow to the optic nerve. The drug may lower the pressure while starving the eye of nourishment.
In 1971, Robert Hepler and Ira Frank published a study in the Journal of the American Medical Association documenting that smoking cannabis reduced intraocular pressure (IOP) in healthy subjects. The reduction was significant, typically 25 to 30 percent from baseline, and occurred within 30 to 60 minutes of smoking.
This was a legitimate finding. Glaucoma is a group of eye diseases characterized by progressive damage to the optic nerve, and elevated IOP is the primary modifiable risk factor. Reducing IOP slows or prevents optic nerve damage and vision loss. At the time, the available treatments for glaucoma were limited, with significant side effects and inconsistent efficacy. A natural substance that could lower IOP by 25 to 30 percent was genuinely interesting.
The finding was replicated in subsequent studies. Both THC and other cannabinoids were shown to reduce IOP when administered by various routes, including smoking, oral ingestion, intravenous injection, and even topical application to the eye (though topical formulations proved difficult due to poor solubility and ocular irritation).
The Mechanism: How Cannabis Lowers IOP
Intraocular pressure is determined by the balance between the production of aqueous humor (the fluid that fills the front chamber of the eye) and its drainage through the trabecular meshwork and uveoscleral outflow pathways. Glaucoma typically involves impaired drainage, leading to fluid buildup and pressure elevation.
Cannabis appears to lower IOP through multiple mechanisms. THC causes vasodilation in ocular blood vessels, which may facilitate aqueous humor outflow. CB1 receptors are present in the ciliary body (which produces aqueous humor) and in the trabecular meshwork (the primary drainage structure). Activation of these receptors may reduce aqueous production and enhance outflow.
The effect is real and reproducible. The problem is not whether cannabis lowers IOP. It clearly does. The problems are how long the effect lasts, what it takes to maintain it, and what the systemic consequences are.
The Duration Problem: 3 to 4 Hours
The IOP-lowering effect of cannabis lasts approximately 3 to 4 hours. After that, pressure returns to baseline. Glaucoma is a 24-hour disease. The optic nerve is vulnerable to pressure elevation at all times, including during sleep when IOP naturally tends to rise.
To maintain consistent IOP reduction throughout a 24-hour period, a patient would need to dose cannabis every 3 to 4 hours, including waking up during the night. That is 6 to 8 doses per day. Each dose would need to contain enough THC to produce a meaningful IOP reduction, which means each dose would also produce psychoactive effects.
The practical implications of this are staggering. A patient maintaining cannabis-based IOP control would be functionally impaired for most of every day. They could not drive safely, maintain most jobs, or function normally in society. The cognitive and psychomotor effects of chronic, round-the-clock THC dosing would constitute a disability in themselves.
This is not a theoretical objection. It is the central practical reason why cannabis was never developed as a glaucoma treatment despite the real IOP-lowering effect. The dosing requirement makes it incompatible with normal life.
Modern Glaucoma Treatments: Why They Win
The glaucoma treatment landscape has changed dramatically since 1971. Modern treatments provide sustained IOP reduction with far greater convenience and fewer systemic effects.
Prostaglandin analog eye drops (latanoprost, travoprost, bimatoprost) are the current first-line treatment. They are applied once daily, typically at bedtime, and reduce IOP by 25 to 33 percent. This is comparable to the IOP reduction from cannabis, but it lasts 24 hours from a single drop with no psychoactive effects. The side effects are local: darkening of the iris, eyelash growth, and occasional eye irritation.
Beta-blocker eye drops (timolol) have been available since the 1970s and provide 20 to 25 percent IOP reduction with twice-daily dosing. They can have systemic effects (reduced heart rate, exacerbation of asthma) but do not impair cognition.
Selective laser trabeculoplasty (SLT) is a procedure that improves aqueous humor drainage through the trabecular meshwork. It is performed in an outpatient setting, takes minutes, and provides IOP reduction lasting months to years. It can be repeated and has minimal side effects.
Minimally invasive glaucoma surgery (MIGS) procedures have expanded the surgical options for glaucoma significantly. Devices like the iStent create new drainage pathways with minimal tissue disruption and can be combined with cataract surgery.
Against this backdrop, the idea of using cannabis as a glaucoma treatment is not just outdated. It is clinically indefensible. Modern treatments are more effective, more convenient, longer-lasting, and have fewer systemic effects. There is no clinical scenario where cannabis would be the optimal choice for IOP reduction.
The Blood Pressure Concern
Beyond the duration problem, there is a more insidious concern about cannabis and glaucoma: the systemic blood pressure effect.
THC causes acute vasodilation and can lower systemic blood pressure. Ocular perfusion pressure, the pressure that drives blood flow to the optic nerve, is determined by the difference between arterial blood pressure and intraocular pressure. If cannabis lowers both IOP and blood pressure simultaneously, the net effect on ocular perfusion pressure may be neutral or even negative.
A 2018 study by Tomida and colleagues found that CBD, which does not lower IOP, actually increased IOP at some doses. More concerning, THC's blood pressure-lowering effect was clinically significant, raising the possibility that any IOP benefit from THC could be offset by reduced blood flow to the optic nerve.
This is a critical point that is often missed in cannabis advocacy. Lowering IOP is beneficial only if it does not simultaneously compromise the blood supply to the tissue you are trying to protect. The optic nerve head is exquisitely sensitive to perfusion pressure, and glaucoma patients already have compromised autoregulation of ocular blood flow. Adding a systemic vasodilator that drops blood pressure may actually worsen optic nerve damage even while reducing IOP.
The AAO Position Statement
The American Academy of Ophthalmology (AAO) has issued a clear position statement on marijuana and glaucoma. The key points are unambiguous.
The AAO does not recommend marijuana or cannabis products for the treatment of glaucoma. Their reasoning includes the short duration of IOP-lowering effect, the need for constant dosing that precludes normal functioning, the systemic side effects of chronic high-dose THC use, the potential reduction in blood supply to the optic nerve, and the availability of effective, well-tolerated conventional treatments.
The Canadian Ophthalmological Society, the European Glaucoma Society, and other major ophthalmological organizations have issued similar positions. There is no significant professional disagreement on this point. The ophthalmology community is unified in not recommending cannabis for glaucoma.
Why the Myth Persists
Despite the clear professional consensus, the belief that cannabis treats glaucoma persists in public consciousness. Several factors contribute to this.
The original finding is real. Cannabis does lower IOP. Patients and advocates who cite this fact are not wrong about the pharmacological effect. They are wrong about its clinical utility, but the distinction between "it works in the lab" and "it works as a treatment" is not intuitive to everyone.
The historical narrative is compelling. Robert Randall's story, legally fighting for access to cannabis to save his vision, is a powerful advocacy narrative that resonated with the medical marijuana movement. The emotional weight of the story carries more cultural influence than the subsequent clinical analysis that showed the approach was impractical.
Glaucoma is common and familiar. It affects millions of people, and most adults know someone with glaucoma. This makes it a relatable condition for cannabis advocacy purposes, even though the medical community has moved on.
Some patients with glaucoma do use cannabis and report benefit. This is likely a combination of the short-term IOP effect, general relaxation and stress reduction, and potentially improved sleep. These benefits are real but they are not specific to glaucoma, and they do not constitute adequate glaucoma management.
Topical Cannabinoid Research
The most scientifically interesting direction for cannabis and glaucoma has been the development of topical cannabinoid eye drops. If cannabinoids could be delivered directly to the eye in a formulation that provided sustained IOP reduction without systemic effects, many of the objections to cannabis for glaucoma would be addressed.
Research groups have worked on this challenge for decades. The barriers are formidable. THC and other cannabinoids are highly lipophilic, which makes them difficult to formulate as aqueous eye drops. They are poorly soluble, irritating to ocular tissue, and rapidly degraded. Various approaches, including nanoparticle formulations, cyclodextrin complexes, and prodrug strategies, have been investigated.
Some preclinical work has shown promise. A 2018 study by Taskar and colleagues demonstrated that a cannabinoid-loaded nanoparticle formulation could lower IOP in rabbits with sustained effects. But no topical cannabinoid formulation has advanced to human clinical trials for glaucoma, and the technical challenges remain significant.
If a topical cannabinoid eye drop is eventually developed that provides 24-hour IOP reduction with once or twice-daily dosing and minimal side effects, it would reopen the conversation about cannabis and glaucoma. Until then, the delivery problem is as much a barrier as the duration problem.
The Bottom Line
The cannabis-glaucoma story is a case study in how a real pharmacological finding can be clinically irrelevant. Cannabis lowers IOP. That fact has been established for over 50 years. But the short duration of effect, the impracticality of round-the-clock dosing, the concern about reduced ocular blood flow, and the dramatic superiority of modern glaucoma treatments have made cannabis an obsolete approach to this disease.
The myth persists because the original claim was true, the advocacy narrative was powerful, and the distinction between pharmacological effect and clinical utility is not always obvious to the public. Ophthalmologists have been clear and consistent on this point for decades: cannabis is not a recommended treatment for glaucoma. Patients who rely on it instead of proven therapies are putting their vision at risk.
This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before making any changes to your treatment plan.
The Bottom Line
Evidence review of cannabis for glaucoma covering Hepler/Frank 1971, IOP mechanism, duration problem, modern treatments, blood pressure paradox, AAO position, and topical research. Original finding: Hepler/Frank 1971 JAMA — cannabis reduced IOP 25-30% within 30-60 minutes; replicated across routes (smoking, oral, IV, topical). Mechanism: CB1 receptors in ciliary body and trabecular meshwork; THC vasodilation facilitates aqueous outflow; may reduce aqueous production. Duration problem: IOP reduction lasts only 3-4 hours; 24-hour disease requires 6-8 daily doses; constant functional impairment from round-the-clock THC dosing incompatible with normal life. Modern treatments: prostaglandin analog drops (latanoprost) = once daily, 25-33% reduction, 24-hour control, no cognitive impairment; SLT = months-to-years from single procedure; MIGS; all vastly more practical. Blood pressure paradox: Tomida 2018 — THC lowers systemic BP → reduces ocular perfusion pressure → may worsen optic nerve damage even while lowering IOP; CBD increased IOP at some doses. AAO position: clear statement against cannabis for glaucoma; short duration, constant dosing, systemic effects, blood supply concern, superior alternatives available; Canadian/European societies concur. Topical research: lipophilicity/solubility/irritation barriers; Taskar 2018 nanoparticle formulation lowered IOP in rabbits; no human trials achieved.
Frequently Asked Questions
Sources & References
- 1RTHC-07927·Warjri, Gazella B et al. (2025). “The Endocannabinoid System May Offer a Two-Pronged Approach to Glaucoma: Pressure Reduction and Nerve Protection.” Journal of current glaucoma practice.Study breakdown →PubMed →↩
- 2RTHC-05865·Adamek, Andrew J et al. (2025). “One in Six Eye Clinic Patients Used Cannabis Recently, and Nearly Half With Glaucoma Wanted to Try It.” International ophthalmology.Study breakdown →PubMed →↩
Research Behind This Article
Showing the 2 most relevant studies from our research database.
Role of Endocannabinoids in Glaucoma: A Review.
Warjri, Gazella B · 2025
The endocannabinoid system (including ligands, receptors, and enzymes) is present throughout the visual system from eye to occipital lobe.
An assessment of the prevalence of cannabis use in eye clinic patients and its implications on glaucoma diagnosis and management.
Adamek, Andrew J · 2025
Recent marijuana use (past month): 15.7%.